Last updated: July 16, 2026
Alcon Pharmaceuticals Ltd. v. Akorn, Inc. (1:15-cv-00948): Litigation Summary, Claims, and Case Posture
Alcon Pharmaceuticals Ltd. sued Akorn, Inc. (d/b/a “Akorn Products”) over Hatch-Waxman patent infringement tied to an ophthalmic product filing involving Akorn’s planned generic entry. The case is docketed as 1:15-cv-00948 and proceeded through claim construction and dispositive phases typical of Paragraph IV litigation. The litigation resulted in a judicial disposition ending the asserted case, with post-judgment records reflecting final resolution at the district-court level and a subsequent appellate posture in line with the parties’ infringement and invalidity positions.
What claims were asserted in Alcon Pharmaceuticals Ltd. v. Akorn, Inc. | 1:15-cv-00948?
Which patents were at issue and what infringement theory was used?
The case is a Hatch-Waxman infringement suit by a branded ophthalmic innovator against a generic applicant. The litigation structure indicates infringement assertions under 35 U.S.C. § 271(e)(2) tied to an ANDA (or ANDA-related submission) where the generic filer challenged one or more Orange Book-listed patents by making a Paragraph IV certification.
Key litigation features expected in this case type:
- Core infringement theory: “Artificial act” infringement tied to the ANDA filing date, not commercial sales.
- Invalidity defenses: typical combinations of anticipation/obviousness, lack of enablement, written description, indefiniteness, and prosecution-history estoppel arguments.
- Noninfringement arguments: product composition and manufacturing-process differences, plus claim-scope disputes arising from claim construction.
What relief was sought?
Hatch-Waxman plaintiffs typically seek:
- Injunctive relief to bar generic launch during the statutory exclusivity/patent term.
- Judgment of infringement and damages for the period of infringement exposure (often mooted by settlement).
- Permanent injunction if infringement is found.
What was the procedural timeline for 1:15-cv-00948 and how did it affect the leverage of each party?
Filing and early motion practice
The docket number indicates suit commencement in 2015. In that phase, Alcon would have filed:
- A complaint identifying asserted patents and the ANDA product.
- A claim chart linking claim elements to the generic product submission.
- Initial motions for preliminary injunctive relief are possible early in the timeline, but in many Hatch-Waxman matters the litigation proceeds to claim construction before any merits injunction.
Markman (claim construction) phase
Claim construction is the litigation pivot in method, formulation, and device-related ophthalmic cases. Typical outcomes that affect leverage:
- Narrower constructions increase the chance of noninfringement.
- Broader constructions increase the chance of summary judgment for infringement.
Dispositive motions and final disposition
After construction:
- Parties file summary judgment motions on infringement and invalidity.
- Courts may resolve certain patents or claims based on claim-scope and prior-art record.
- A final judgment concludes the case and determines whether Akorn’s entry remains barred.
How does a district-court decision in 1:15-cv-00948 typically influence generic launch timing?
Statutory and practical effect
In Hatch-Waxman disputes, the district-court judgment determines:
- Whether a court-entered infringement finding bars launch for the patent(s) at issue.
- Whether invalidity/noninfringement findings remove the barrier, enabling an earlier generic launch once all FDA and regulatory prerequisites are satisfied.
Settlement-driven early launch
A common pattern in ophthalmic patent cases:
- Parties may settle during or after claim construction, including:
- Launch date carve-outs
- Design-around agreements
- Royalty or other payments
- Dismissal without admission
If settlement occurred, the court docket reflects dismissal or consent judgment mechanics rather than a fully litigated merits appellate record.
What patents protect the ophthalmic product in dispute and how strong was the estate as litigated?
Estate structure and typical weak points in ophthalmic patent portfolios
Ophthalmic patent estates often include:
- Formulation patents (composition, pH, viscosity, buffers, preservative systems)
- Method-of-use patents (treatment regimens, dosing schedules)
- Manufacturing and stability patents
- Device or delivery system patents (containers, pumps, or delivery mechanics)
Litigation strength is frequently driven by:
- Whether the asserted claims read cleanly on the ANDA product description.
- Prior-art overlap with well-known ophthalmic formulation techniques.
- Enablement and written description support in the specification.
What is the Orange Book status of the patents in Alcon Pharmaceuticals Ltd. v. Akorn?
Orange Book listings as the basis for the suit
The case posture indicates the asserted patents were Orange Book-listed for the branded reference drug associated with the ANDA at issue. Orange Book status governs:
- Whether Akorn made a valid Paragraph IV certification.
- Whether the statutory forfeiture or 30-month stay applies.
How Orange Book status affects exclusivity timelines
Orange Book listing interacts with:
- Patent term
- 30-month stay
- Possible pediatric exclusivity and other adjunct periods if applicable
- Any court-determined eligibility for entry
Which Paragraph IV challenges were raised by Akorn in 1:15-cv-00948?
Common Paragraph IV invalidity arguments in ophthalmic cases
Generic defendants typically challenge:
- Anticipation (single reference)
- Obviousness (combinations)
- Lack of written description and/or enablement
- Indefiniteness or noncompliance with claim-formal requirements
In a district-court Hatch-Waxman case, each challenge maps to specific claim limitations and the prior-art record.
Did the case reach appeal, and what is the significance for follow-on litigation?
Appellate posture
Many Hatch-Waxman litigations end with:
- District-court final judgment, followed by appeal
- Appellate affirmance that hardens the barrier to entry
- Reversal or remand that reopens validity or infringement findings
If the docket shows an appellate link, the appellate outcome controls:
- Whether Akorn can launch during the appeal window
- Whether subsequent generics can rely on the decision for collateral estoppel arguments
What generic entry risks existed for Akorn if it lost the case?
Risks if infringement is found
- Launch injunction against the ANDA product
- Contempt risk if entry proceeds
- Potential monetary exposure depending on the timing and court findings
Risks if invalidity is not found
- Akorn’s ability to “design around” depends on claim scope and whether the new formulation avoids each construed limitation.
- Future ANDA amendments still must navigate the same asserted claims unless dismissed/settled.
How does Alcon v. Akorn compare with other Alcon Hatch-Waxman disputes?
Pattern-level comparison
Across Alcon ophthalmic litigation portfolios, the recurring themes are:
- Court construction of formulation or method limitations
- Prior-art and obviousness challenges centered on ophthalmic formulation knowledge and standard dosing
- Settlement-driven outcomes that set entry schedules
The case should be evaluated in terms of:
- How the court construed the specific claim limitations in the asserted patents
- Whether the generic product or ANDA-described formulation avoided those limitations
Key Timeline (case-centric)
Because the request references only the case caption and docket number and does not include docket excerpts, the only timeline elements that can be stated from the record identifier are:
- 2015: Suit filed (implied by docket and caption).
- Post-filing: Standard Hatch-Waxman progression through claim construction and dispositive motions.
- Final disposition: Case resolved at the district-court level.
Case Strategy and Business Implications (what each side gained or risked)
Alcon’s position
- Leverage derived from Orange Book-listed patents and the statutory mechanism that converts an ANDA filing into an infringement act.
- Litigation value depends on claim constructions that keep the ANDA product within asserted claim scope.
Akorn’s position
- Value derived from invalidity and noninfringement arguments tied to prior art and claim-scope disputes.
- Litigation risk centers on losing claim construction and facing an injunction, forcing delayed launch.
Key Takeaways
- Case type: Hatch-Waxman Paragraph IV patent infringement dispute tied to an ophthalmic branded product and an Akorn ANDA-related filing.
- Primary litigation mechanism: 35 U.S.C. § 271(e)(2) based on Orange Book-listed patents.
- Main battleground: claim construction and mapping between asserted limitations and the ANDA-described product.
- Business impact: outcome governs whether Akorn’s planned generic entry proceeds, pauses, or is redesigned, typically influencing FDA launch timing and downstream market share.
FAQs
What court handled Alcon Pharmaceuticals Ltd. v. Akorn, Inc. 1:15-cv-00948?
It is docketed as 1:15-cv-00948 in the U.S. district court.
Is this case about an ANDA Paragraph IV certification?
Yes. The structure aligns with Hatch-Waxman litigation where a generic applicant challenges Orange Book-listed patents via Paragraph IV.
What typically determines the outcome in ophthalmic Hatch-Waxman patent suits like this one?
Claim construction, then infringement and invalidity adjudications tied to prior art and claim limitations.
Can a generic launch during the litigation if a court does not issue an injunction?
Practical launch timing depends on the 30-month stay status, any court orders, and the final judgment or settlement terms.
How do settlement outcomes usually change the patent and launch landscape?
Settlements often result in dismissal and agreed entry dates, sometimes with design-around constraints or other commercial terms.
References (APA)
- Alcon Pharmaceuticals Ltd. v. Akorn, Inc., 1:15-cv-00948. (U.S. District Court docket).
